# A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Pa

Source: https://onco.cc/trials/nct07502300/  
OnCo record `nct07502300` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Izalontamab brengitecan, Tislelizumab, Carboplatin in small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) is a phase 3 interventional study registered as NCT07502300 by Sichuan Baili Pharmaceutical Co., Ltd., with 562 participants planned, started 2026-06-15 and due to reach its primary completion in 2029-12. Interventions recorded: BL-B01D1, Tislelizumab, Carboplatin, Etoposide. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07502300
- Phase: 3
- Setting: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 for Injection Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer
- Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
- Enrolled: 562

## Sources

- ClinicalTrials.gov NCT07502300: https://clinicaltrials.gov/study/NCT07502300

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- companies: [SystImmune / Sichuan Biokin](https://onco.cc/companies/systimmune/)

---
JSON: https://onco.cc/api/v1/entities/nct07502300.json